FDA Uncertain About GSK’s Serevent Pediatric Risk-Benefit Ratio
This article was originally published in The Pink Sheet Daily
Executive Summary
Pediatric Advisory Committee will review adverse events data for the asthma treatment Serevent and the adequacy of pediatric risk information in the drug’s labeling.